Details
Category: Volume 06 Issue 08 August 2018
Hits: 1428

Title: A study on safety and efficacy of Deferasirox, an oral iron chelator in the treatment of transfusion haemosiderosis in children with β-Thalassemia Major in a tertiary care rural hospital

Authors: Srinivas Mathur, Dr Sanjay Shukla, Dr Rachna Sabale, Dr Sayed Asif Umar

 DOI:  https://dx.doi.org/10.18535/jmscr/v6i8.08

Abstract

Background: β-Thalassemia major is a hereditary hemolytic anaemia (and the commonest transfusion dependent anaemia) which continues to be a major cause of morbidity and mortality in developing countries like India. Deferasirox is a tridentate, once-daily, oral iron chelator that is widely used in the management of patients with transfusion haemosiderosis. Chelation therapy is usually started after 10-20 transfusions or when serum ferritin level reaches 1000 μg/L [Deferasirox has demonstrated consistent dose-dependent efficacy, producing sustained reductions in serum ferritin 6].

Aims and objective

Aim: To study the safety and efficacy of Deferasirox in transfusion haemosiderosis in children with β-Thalassemia.

Objectives 1. To assess the serum ferritin levels in multi-transfused β-Thalassemia patients who are on treatment with Deferasirox. 2. To study the efficacy of Deferasirox in patients admitted with transfusion haemosiderosis in β-Thalassemia. 3. To estimate iron overload in the patients admitted with transfusion haemosiderosis in β-Thalassemia. 4. To study the adverse effect profile andfinal outcome of administration of Deferasirox in patients with transfusion haemosiderosis in β-Thalassemia.

Study Period: 6 months (After the approval from IEC- RMC)

Sample Size: 100Results and Observation there was adecrease in serum ferritin from 4049.87ng/ml to 3647.4ng/ml this was a significant change with a p value 0f 0.0001. Furthermore, a significant negative correlation was observed between the mean dose of deferasirox prescribed and the mean serum ferritin levels. %). Diarrhoea was reported as the most common) in our study it was found that the mean change in the serum creatinine values increased from 0.475 to0.487(table7) in our study this change was not significant(table6)the findings for sodium and serum potassium were not considered significant (table 7 and 8) in our study .awareness among prescribers about ADRs of deferasirox and frequent monitoring of serum ferritin and serum iron levels as a guide to determine its dose is required to improve tolerability of this important and necessary drug.further multi-centered studies with more sample size are needed.

References

  1. Mohanty D, Colah RB, Gorakshakar AC, et al. Prevalence of beta-thalassemia and other haemoglobinopathies in six cities in India: a multicentre study. J Community Genet. 2013;4:33–42.
  2. Mariani R, Trombini P, Pozzi M, et al. Iron metabolism in thalassemia and sickle cell disease. Mediterr J Hematol Infect Dis. 2009;1:006–006.
  3. Fung EB, Harmatz P, Milet M, et al. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am J Hematol.2007;82:255–65.
  4. Riaz H, Riaz T, Khan MU, et al. Serum ferritin levels, socio-demographic factors and desferrioxamine therapy in multi-transfused thalassemia major patients at a government tertiary care hospital of Karachi, Pakistan. BMC research notes. 2011;4:287–287.
  5. Taksande A, Prabhu S, Venkatesh S. Cardiovascular Aspect of Beta-Thalassaemia. CardiovascHematol Agents Med Chem. 2012;10:25–30.
  6. NC Joshi, Common clinical cases (part II), Case 1: Beta Thalassemia, Clinical Pediat-rics, Second edition, 2012, page 259-281.
  7. Iancu TC, Neustein HB, Landing BH. The liver in thalassemia major: ultra structural observations. in Iron Metabolism, Ciba Foundation Symposium 51 Elsevier ExcerptaMedica North Holland publishers 1977; 1(1): 293-316.
  8. Jean G, Terzoli S, Mauri R, et al. Cirrhosis associated with multiple transfusions in thalassaemia. Arch. Dis. Child. 1984; 59(1): 67-70.
  9. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann NY Acad Sci. 1998; 850(1): 227-31.
  10. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997; 89(3): 739-61.
  11. Olivieri NF. The ß-thalassemias. N Engl J Med. 1999; 341(2): 99-109.
  12. Porter JB. Practical management of iron overload.Br J Haematol. 2001; 115(2): 239-52.
  13. National Institutes of Health. Management and therapy of sickle cell disease.National Heart, Lung, and Blood Institute. 4th NIH Publication. 2002; 333(4): 96-17.
  14. McLaren GD, Muir WA, Kellermeyer RW. Iron overloads disorders: natural history, pathogenesis, diagnosis, and therapy. Crit Rev Clin Lab Sci. 1983; 19(3): 205-66.
  15. Prati D, Maggioni M, Milani S, et al. Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica. 2004; 89(10): 1179-86.
  16. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic severe refractory anaemia with hemochromatosis. Circulation 1964; 30(5): 698- 705.
  17. Schrier SL, Angelucci E. New strategies in the treatment of thalassemias.Annu Rev Med. 2005; 56(1): 157-71.
  18. Cappellini MD, Zanaboni L. Efficacy and Safety of Deferasirox. Transfusion Iron Chelation Therapy, US Hematology. Touch Briefing 2009; 107(9): 68-73.
  19. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with Deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. ClinTher. 2007; 29(5): 909–17.
  20. Vichinsky E, Onyekwere O, Porter J, et al. A randomized comparison of Deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007; 136(3): 501–8.
  21. Cappellini MD, Giardina P, Porter J, et al. Long-term safety and tolerability of the once-daily, oral iron chelator Deferasirox (Exjade1, ICL670) in patients with transfusional iron overload. Blood 2006; 108(1): 501a
  22. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oraliron chelator, in patients with beta-thalassemia.Blood. 2006;107: 3455–62
  23. Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, et al. Efficacy ofdeferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood.2010;115:2364–71. [PubMed]
  24. Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: TheESCALATOR study. Eur J Haematol. 2009;82:458–65. [PMC free article] [PubMed]

Corresponding Author

Dr Sanjay Shukla